Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

XtalPi, a US-China Ai Drug Discovery Company, Closes $319 Million C Round

publication date: Sep 28, 2020

XtalPi, an AI drug discovery and development company, closed a $318.8 million oversubscribed Series C funding co-led by SoftBank Vision Fund2, PICC Capital and Morningside. The company uses its expertise in crystal structures plus quantum physics, AI and cloud computing to develop new drugs. XtalPi's model combines physics-based concepts with data from labs. Because the three founders met at MIT, the company's headquarters are in Cambridge, MA, though its computational R&D center and experimental center are in Shenzhen. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital